Brief: Fosun Pharma Says Henlius Signs Licensing Agreement With Eisai
05/02/2026 08:41
Feb 5 (Reuters) - Shanghai Fosun Pharmaceutical 600196.SS: SAYS HENLIUS BIOTECH SIGNS LICENSING AGREEMENT WITH EISAI SAYS HENLIUS GRANTS EISAI RIGHTS TO DEVELOP, PRODUCE, COMMERCIALIZE SERPLULIMAB INJECTION Source text Further company coverage: 600196.SS (Reporting by Beijing Newsroom) ((Ethan.Wang@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China